Management of obesity and obesity-associated comorbidities in the child and adolescent population

Czech version

Authors: Miriam Kuricová ^1,2,3; ; Martin Čillík ¹; Gabriela Tóthová ¹; Anna Pavlíková ¹; Andrea Mešťaníková ¹; Jana Poddaná ¹; Dana Černochová ¹; Eva Mendelová ¹; Dominika Mišíková ¹; Andrea Botíková ³
Authors‘ workplace: Detské oddelenie NEDÚ, n. o., Ľubochňa ¹; Klinika detí a dorastu, Jesseniova LF UK a UNM, Martin ²; Katedra ošetrovateľstva, Fakulta zdravotníctva a sociálnej práce Trnavskej univerzity v Trnave ³
Published in: Forum Diab 2025; 14(1): 37-45
Category: Review Article

Overview

This paper addresses prevalence, diagnosis and management of obesity and obesity-associated comorbidities in the child and adolescent population. In addition to the standard spectrum of therapeutic options (individual or group lifestyle modification, nutritional recommendations, physical activity modification, cognitive-behavioral therapy and psychological intervention) the drug treatment with liraglutide has been available in Slovakia for adolescents with obesity since 2022. Due to the increasing trend of the disease, up to fourth comes the need of creating a new healthcare infrastructure for adolescents with obesity. The European Association for the Study of Obesity (EASO) has published criteria for obesity management centers with the aim of improving the care of patients with obesity.

Keywords:

comorbidity – liraglutide – Adolescents – children – (pre)obesity

Sources

Rubino F, Cummings DE, Eckel R et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 2025; 13(3): 221–262. Dostupné z DOI: <https://doi.org/10.1016/S2213–8587(24)00316–4>. Erratum in: Lancet Diabetes Endocrinol 2025; 13(3): e6. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(25)00006–3>..

Freedman DS, Mei Z, Srinivasan SR et al Cardiovascular risk factor and excess adiposity among overweight children and adolescents. J Pediatr 2007; 150(1): 12–17_2e. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jpeds.2006.08.042>.

Madarasová-Gecková D, Husárová D, Bakalár P et al. Sociálne determinanty zdravia školákov. HBSC Slovensko 2021/2022. ISBN9788057402145. Dostupné z DOI: <http:///dx.doi.org/10.33542/SDZ-0214–5>.

Odborné usmernenie MZ SR o diagnostike a liečbe obezity u detí. Vestník MZ SR, čiastka 6–15, 31.3.2012, ročník 60, normatívna časť 7, č. 13278-OZS-2011. Dostupné z WWW: <https://www.epi.sk/vestnik-mzsr/2012–7>.

Kobzová J, Vignerová J, Bláha P et al. The 6th nationwide anthropological survay of children and adolescents in the Czech Republic in 2001. Cent Eur J Public Health 2004;12(3):126–130. Dostupné z WWW: <https://cejph.szu.cz/artkey/cjp-200403–0006_The-6th-Nationwide-Anthropological-Survey-of-Children-and-Adolescents-in-the-Czech-Republic-in-2001.php>.

Skinner AC, Ravanbakht SN, Skelton JA et al. Prevalence of obesity and severe obesity in US children, 1999–2016. Pediatrics 2018; 141(3): e20173459. Dostupné z DOI: <https://dx.doi.org/10.1542/peds.2017–3459>.

Cole TJ, Lobstein T. Extended international (IOTF) body mass index cut offs for thinness, overweight and obesity. Pediatr Obes 2012; 7(4): 284–294. Dostupné z DOI: <http://dx.doi.org/10.1111/j.2047–6310.2012.00064.x>.

Stupnicky R, Tomaszewski P, Milde K et al. Waist-to-height ratio /WHTR): Proposed approach to establishing reference values for children and youth. Paper of Anthropology 2013; 22: 214–224. Dostupné z DOI: <https://doi.org/10.12697/poa.2013.22.23>.

Staníková D, Staník J. (Pre)obezita v detstve a adolescencii. In: Fábryová Ľ (ed) et al. Klinická obezitológia. Facta Medica: Brno 2023: 417–427. ISBN 978–80–88056–16–4.

Petrocová P, Majerčák I, Šlepecký I. Komplexný manažment detského a adolescentného pacienta s obezitou a nadváhou. Štandardný diagnostický, preventívny a liečebný postup. OPS: Klinická psychológia pre deti a dorast. 1. 7. 2022. Dostupné z WWW: <https: www.health.gov.sk>.

American Diabetes Association Professional Practice Committee: 7. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Care in Diabetes – 2024. Diabetes Care 2024; 47(Suppl 1): S145-S157. Dostupné z DOI: <http://dx.doi.org/10.2337/dc24-S008>.

Kelly AS, Auerbach P, Barrientos-Perez M et al. [NN8022–4180 Trial Investigators]. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med 2020; 382(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1916038>.

Jacobsen LV, Flint A, Olsen AK et al. Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics. Clin Pharmacokinet 2016; 55(6): 657–672. Dostupné z DOI: <http://dx.doi.org/10.1007/s40262–015–0343–6>.

le Roux CW, Astrup A, Fujioka K et al. [SCALE Obesity Prediabetes NN8022–1839 Study Group]. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017; 389(10077): 1399–1409. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(17)30069–7>.

Pi-Sunyer X, Astrup A, Fujioka K et al. [SCALE Obesity and Prediabetes NN8022–1839 Study Group]. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015; 373(1): 11–22. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1411892>.

Davies MJ, Bergenstal R, Bode B et al. [NN8022–1922 Study Group]. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA 2015; 314(7): 687–699. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2015.9676>.

Blackman A, Foster GD, Zammit G et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond) 2016; 40(8): 1310–1319. Dostupné z DOI: <http://dx.doi.org/10.1038/ijo.2016.52>.

Marso SP, Daniels GH, Brown-Frandsen K et al. [LEADER Steering Committee; LEADER Trial Investigators]. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375(4): 311–322. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1603827>.

Elkind-Hirsch KE, Chappell N, Shaler D et al. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertil Steril 2022; 118(2): 371–381. Dostupné z DOI: <http://dx.doi.org/10.1016/j.fertnstert.2022.04.027>.

Livadas S, Androulakis I, Angelopoulos N et al. Liraglutide administration improves hormonal/metabolic profile and reproductive features in women with HAIR-AN syndrome. Endocrinol Diabetes Metab Case Rep 2020; 2020: 19–0150. Dostupné z DOI: <http://dx.doi.org/10.1530/EDM-19–0150>.

Fox CK, Barrientos-Pérez M, Bomberg EM et al. [SCALE Kids Trial Group]. Liraglutide for Children 6 to <12 Years of Age with Obesity – A Randomized Trial. N Engl J Med 2025; 392(6): 555–565. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2407379>.

Bjornstad P, Drews KL, Caprio S et al. [TODAY Study Group]. Long-term complication in youth-onset type 2 diabetes. N Engl J Med 2021; 385(5): 416–426. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2100165>.

Styne DM, Arslanian SA, Connor ELet al. Pediatric obesity – assessment, treatment and prevention. An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2017; 102(3): 709–757. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2016–2573>.

Busseto L, Dicker D, Frühbeck G et al. A new framework for the diagnosis, staging and management of obesity in adults. Nat Med 2024; 30(9): 2395–2399. Dostupné z DOI: <http://dx.doi.org/10.1038/s41591–024–03095–3>.

EASO. EASO Response to the Lancet Commission Report on Obesity Diagnosis and Management. Dostupné z WWW: <https://easo.org/easo-response-to-the-lancet-commission-report-on-obesity-diagnosis-and-management/>.